top of page
News, Events and Updates
Search
US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Nov 7, 2022
Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress
Oct 17, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 23, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 9, 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 31, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
Jun 8, 2022
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Apr 27, 2022
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Mar 15, 2022
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial
Feb 4, 2022
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Aug 12, 2021
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73
Jan 11, 2021
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
